Cargando…

Poorly differentiated thyroid carcinoma: a clinician’s perspective

Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid carcinoma originating from follicular epithelial cells. No explicit consensus can be achieved to date due to sparse clinical data, potentially compromising the outcomes of patients. In this comprehensive review from a clinician’s persp...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Junyu, Ruan, Maomei, Jin, Yuchen, Fu, Hao, Cheng, Lin, Luo, Qiong, Liu, Zhiyan, Lv, Zhongwei, Chen, Libo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010806/
https://www.ncbi.nlm.nih.gov/pubmed/35195082
http://dx.doi.org/10.1530/ETJ-22-0021
_version_ 1784687563224645632
author Tong, Junyu
Ruan, Maomei
Jin, Yuchen
Fu, Hao
Cheng, Lin
Luo, Qiong
Liu, Zhiyan
Lv, Zhongwei
Chen, Libo
author_facet Tong, Junyu
Ruan, Maomei
Jin, Yuchen
Fu, Hao
Cheng, Lin
Luo, Qiong
Liu, Zhiyan
Lv, Zhongwei
Chen, Libo
author_sort Tong, Junyu
collection PubMed
description Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid carcinoma originating from follicular epithelial cells. No explicit consensus can be achieved to date due to sparse clinical data, potentially compromising the outcomes of patients. In this comprehensive review from a clinician’s perspective, the epidemiology and prognosis are described, diagnosis based on manifestations, pathology, and medical imaging are discussed, and both traditional and emerging therapeutics are addressed as well. Turin consensus remains the mainstay diagnostic criteria for PDTC, and individualized assessments are decisive for treatment option. The prognosis is optimal if complete resection is performed at early stage but dismal in nearly half of patients with locally advanced and/or distant metastatic diseases, in which adjuvant therapies such as (131)I therapy, external beam radiation therapy, and chemotherapy should be incorporated. Emerging therapeutics including molecular targeted therapy, differentiation therapy, and immunotherapy deserve further investigations to improve the prognosis of PDTC patients with advanced disease.
format Online
Article
Text
id pubmed-9010806
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-90108062022-04-18 Poorly differentiated thyroid carcinoma: a clinician’s perspective Tong, Junyu Ruan, Maomei Jin, Yuchen Fu, Hao Cheng, Lin Luo, Qiong Liu, Zhiyan Lv, Zhongwei Chen, Libo Eur Thyroid J Review Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid carcinoma originating from follicular epithelial cells. No explicit consensus can be achieved to date due to sparse clinical data, potentially compromising the outcomes of patients. In this comprehensive review from a clinician’s perspective, the epidemiology and prognosis are described, diagnosis based on manifestations, pathology, and medical imaging are discussed, and both traditional and emerging therapeutics are addressed as well. Turin consensus remains the mainstay diagnostic criteria for PDTC, and individualized assessments are decisive for treatment option. The prognosis is optimal if complete resection is performed at early stage but dismal in nearly half of patients with locally advanced and/or distant metastatic diseases, in which adjuvant therapies such as (131)I therapy, external beam radiation therapy, and chemotherapy should be incorporated. Emerging therapeutics including molecular targeted therapy, differentiation therapy, and immunotherapy deserve further investigations to improve the prognosis of PDTC patients with advanced disease. Bioscientifica Ltd 2022-02-22 /pmc/articles/PMC9010806/ /pubmed/35195082 http://dx.doi.org/10.1530/ETJ-22-0021 Text en © The authors https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Review
Tong, Junyu
Ruan, Maomei
Jin, Yuchen
Fu, Hao
Cheng, Lin
Luo, Qiong
Liu, Zhiyan
Lv, Zhongwei
Chen, Libo
Poorly differentiated thyroid carcinoma: a clinician’s perspective
title Poorly differentiated thyroid carcinoma: a clinician’s perspective
title_full Poorly differentiated thyroid carcinoma: a clinician’s perspective
title_fullStr Poorly differentiated thyroid carcinoma: a clinician’s perspective
title_full_unstemmed Poorly differentiated thyroid carcinoma: a clinician’s perspective
title_short Poorly differentiated thyroid carcinoma: a clinician’s perspective
title_sort poorly differentiated thyroid carcinoma: a clinician’s perspective
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010806/
https://www.ncbi.nlm.nih.gov/pubmed/35195082
http://dx.doi.org/10.1530/ETJ-22-0021
work_keys_str_mv AT tongjunyu poorlydifferentiatedthyroidcarcinomaacliniciansperspective
AT ruanmaomei poorlydifferentiatedthyroidcarcinomaacliniciansperspective
AT jinyuchen poorlydifferentiatedthyroidcarcinomaacliniciansperspective
AT fuhao poorlydifferentiatedthyroidcarcinomaacliniciansperspective
AT chenglin poorlydifferentiatedthyroidcarcinomaacliniciansperspective
AT luoqiong poorlydifferentiatedthyroidcarcinomaacliniciansperspective
AT liuzhiyan poorlydifferentiatedthyroidcarcinomaacliniciansperspective
AT lvzhongwei poorlydifferentiatedthyroidcarcinomaacliniciansperspective
AT chenlibo poorlydifferentiatedthyroidcarcinomaacliniciansperspective